对耐药癌细胞的有效和靶向治疗提出了重大挑战。由于铁代谢和氧化应激水平升高，靶向细胞铁死亡对抗凋亡肿瘤具有显着疗效。然而，各种障碍限制了其有效性。为了克服这些挑战并增强癌细胞的铁死亡，我们开发了一种自供电光动力治疗片剂，其中集成了铁死亡诱导剂 (FIN)、咪唑酮erastin (IKE)。 FIN 通过增加氧化应激和脂质过氧化来增强光动力疗法 (PDT) 的敏感性。此外，他们利用芬顿反应补充氧气，在 PDT 过程中产生更多的活性氧 (ROS)。此外，PDT 促进铁离子从不稳定铁库 (LIP) 中释放，加速脂质过氧化并诱导铁死亡。体外和体内实验均显示85%以上的肿瘤抑制率。这种协同治疗方法不仅解决了与 PDT 相关的渗透不足和肿瘤缺氧的局限性，而且还减少了所需的药物剂量。其对靶细胞的高效性和特异性最大限度地减少了副作用，为对抗癌症治疗中的临床耐药性提供了一种新方法。© 2023 作者。 《先进科学》由 Wiley-VCH GmbH 出版。

The effective and targeted treatment of resistant cancer cells presents a significant challenge. Targeting cell ferroptosis has shown remarkable efficacy against apoptosis-resistant tumors due to their elevated iron metabolism and oxidative stress levels. However, various obstacles have limited its effectiveness. To overcome these challenges and enhance ferroptosis in cancer cells, we have developed a self-powered photodynamic therapeutic tablet that integrates a ferroptosis inducer (FIN), imidazole ketone erastin (IKE). FINs augment the sensitivity of photodynamic therapy (PDT) by increasing oxidative stress and lipid peroxidation. Furthermore, they utilize the Fenton reaction to supplement oxygen, generating a greater amount of reactive oxygen species (ROS) during PDT. Additionally, PDT facilitates the release of iron ions from the labile iron pool (LIP), accelerating lipid peroxidation and inducing ferroptosis. In vitro and in vivo experiments have demonstrated a more than 85% tumor inhibition rate. This synergistic treatment approach not only addresses the limitations of inadequate penetration and tumor hypoxia associated with PDT but also reduces the required medication dosage. Its high efficiency and specificity towards targeted cells minimize adverse effects, presenting a novel approach to combat clinical resistance in cancer treatment.© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.